Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of zolbetuximab plus mFOLFOX6 versus placebo plus mFOLFOX6 in first-line CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
MOH_2019-03-14_002441Phase 3Recruiting
- Sponsor
- Astellas Pharma
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing mFOLFOX6 plus zolbetuximab with mFOLFOX6 plus placebo (2 arms). Started Jul 2018; status: recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on MOH_2019-03-14_002441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-14_002441.